Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
98 hedge funds and large institutions have $1.52B invested in Soleno Therapeutics in 2024 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 40 increasing their positions, 16 reducing their positions, and 10 closing their positions.
314% more call options, than puts
Call options by funds: $17.1M | Put options by funds: $4.14M
220% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 10
150% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 16
29% more funds holding
Funds holding: 76 → 98 (+22)
20% more capital invested
Capital invested by funds: $1.27B → $1.52B (+$253M)
6.33% more ownership
Funds ownership: 103.15% → 109.48% (+6.3%)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carlyle Group
Washington,
District of Columbia
|
+$54.9M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$38M |
| 3 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$24.9M |
| 4 |
State Street
Boston,
Massachusetts
|
+$21.2M |
| 5 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$18.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$35.1M |
| 2 |
CC
Commodore Capital
New York
|
-$24M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$20.2M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$6.22M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$4.23M |
SLNO Hedge Fund Activity: Q1 2024 in Review
98 of the 6,948 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q1 2024, worth a combined $1.52B — up 20% from $1.27B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new SLNO positions and 10 closed out — a net gain of 22 holders — while 40 added to existing stakes and 16 trimmed.
The largest buyer was Carlyle Group, adding an estimated $54.9M. The largest seller was Balyasny Asset Management, cutting an estimated $35.1M.
- 98 institutional investors held Soleno Therapeutics (SLNO) as of Q1 2024, up from 76 in Q4 2023.
- Funds reported $1.52B of Soleno Therapeutics stock for Q1 2024, up 20% quarter-over-quarter.
- 32 funds opened new Soleno Therapeutics positions in Q1 2024 and 10 closed out, a net change of +22 holders.
- The largest Soleno Therapeutics buyer in Q1 2024 was Carlyle Group, an estimated $54.9M added.
- The largest Soleno Therapeutics seller in Q1 2024 was Balyasny Asset Management, an estimated $35.1M sold.
Based on aggregated 13F filings for Q1 2024.